Figure 4From: Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitroCell apoptosis. (A). OCUM-2MD3/L-OHP (Control group); (B). OCUM-2MD3 (Control group); (C). OCUM-2MD3/L-OHP (Treatment group); (D). OCUM-2MD3 (Treatment group).Back to article page